News

The sickle cell disease (SCD) treatment program at Loma Linda University Children’s Hospital in California has been recognized as a center of excellence, joining dozens of other centers in the U.S. affiliated with the National Alliance for Sickle Cell Centers (NASCC). The NASCC identifies “member” centers based on…

The addition of briquilimab, Jasper Therapeutics’ investigational conditioning therapy, improved the success of a stem cell transplant in people with sickle cell disease (SCD), early data from the first three patients in a Phase 1/2 trial show. According to the company, two of the three patients, all treated…

Adding omega-3 or vitamin D supplements boosts the therapeutic effectiveness of standard of care therapy for sickle cell disease (SCD) children with vaso-occlusive crises (VOCs), a recent study shows. Omega-3 supplements reduced the number and severity of VOCs, while vitamin D lessened their severity only. Supplementation also reduced the…

We at Sickle Cell Anemia News have brought you coverage of the latest developments in research and advances in treatment related to sickle cell disease (SCD) in 2022. We look forward to continuing being a resource for the sickle cell community in 2023. Here we’ve compiled a list of the…

Bluebird bio will resume its study of lovotibeglogene autotemcel (lovo-cel) in children and adolescents with sickle cell disease (SCD) following the U.S. Food and Drug Administration’s (FDA’s) lifting of its yearlong partial clinical hold for patients under age 18. The temporary holdup stemmed from an investigation into…

UC San Diego Health has won the 2022 California Association of Public Hospitals and Health Systems (CAPH) Quality Leaders Award in the health equity category for its  same-day outpatient infusion program, which seeks to mitigate healthcare disparities in sickle cell disease (SCD). Each year, the CAPH recognizes initiatives by…

An imbalance of microbes in the digestive tract was found to contribute to bone disease in a mouse model study of sickle cell disease. Researchers discovered that transplanting healthy gut microbes protected the animals against SCD-related bone loss by increasing the levels of a bone growth hormone, which rose in…

New preclinical data support the ability of the ESCAPE platform, an approach Beam Therapeutics is advancing, to more safely prepare people with sickle cell disease (SCD) for gene-editing treatments now in development. Notably, these studies represent the first in vivo data for ESCAPE — that is, the experimental platform’s first evaluation in living…

A lung ultrasound may help in diagnosing acute chest syndrome (ACS), a serious lung complication in sickle cell disease (SCD), a pooled analysis of studies suggests. In fact, according to researchers, a lung ultrasound may be a better option than repeated chest X-rays to support an ACS diagnosis. An…

The experimental gene-editing therapy EDIT-301 appears to be working largely as expected in the first two sickle cell disease (SCD) patients treated as part of the Phase 1/2 RUBY trial, according to new data shared by the therapy’s developer, Editas Medicine. “These promising clinical results from the RUBY…